tbuckley/cabot-search huggingface dataset:
TCT-341 Clinical Significance of Post-Stent Intravascular Ultrasound for Chronic Total Occlusion Percutaneous Coronary Intervention With Drug-Eluting Stents
Authors: Sang-Cheol Cho, Yeongjin Jeong, Junghoon Lee, Yujin Yang, KyungJin Choe, Ju Hyeon Kim, Euihong Ko, Sangwoo Park, Junho Hyun, Do-Yoon Kang, Jung-Min Ahn, Pil Hyung Lee, Duk-Woo Park, Seung-Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2019)
TCT-96 Tricuspid Valve-in-Valve and Bioprosthetic Surgical Tricuspid and Pulmonic Valve Degeneration: Lessons From Imaging and Histopathology
Authors: Stephanie Sellers, Tim Cartlidge, Mark Hensey, Christopher Turner, Althea Lai, Karen Lau, Janarthanan Sathananthan, Philipp Blanke, David Granville, Bruce McManus, John Webb, David Newby, Marc Dweck, Jonathon Leipsic
Journal: Journal of the American College of Cardiology (2019)
Patterns of Genomic Differentiation in the Drosophila nasuta Species Complex
Authors: Dat Mai, Matthew J Nalley, Doris Bachtrog
Journal: Molecular Biology and Evolution (2019)

Abstract The Drosophila nasuta species complex contains over a dozen recently diverged species that are distributed widely across South-East Asia, and which shows varying degrees of pre- and postzygotic isolation. Here, we assemble a high-quality genome for D. albomicans using single-molecule sequencing and chromatin conformation capture, and draft genomes for 11 additional species and 67 individuals across the clade, to infer the species phylogeny and patterns of genetic diversity in this group. Our assembly recovers entire chromosomes, and we date the origin of this radiation ∼2 Ma. Despite low levels of overall differentiation, most species or subspecies show clear clustering into their designated taxonomic groups using population genetics and phylogenetic methods. Local evolutionary history is heterogeneous across the genome, and differs between the autosomes and the X chromosome for species in the sulfurigaster subgroup, likely due to autosomal introgression. Our study establishes the nasuta species complex as a promising model system to further characterize the evolution of pre- and postzygotic isolation in this clade.
Adjuvant Therapy for <i>HER2</i>-Positive Breast Cancer
Authors: Anita Slomski
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A patient has complained about me online. What should I do?
Authors: Abi Rimmer
Journal: BMJ (2019)

A patient has complained about me online. What should I do?It can be upsetting and unsettling to receive a complaint from a patient online.Abi Rimmer speaks to experts on how best to deal with it Abi RimmerThe BMJ "Maintain patient confidentiality"Ellie Mein, medicolegal adviser at the Medical Defence Union, says, "Unfortunately, online complaints are becoming increasingly common and can be upsetting.Feedback can range from mild dissatisfaction through to abusive comments, so how you approach it will depend on the nature of the complaint.
Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia
Authors: Vivek Kumar, Sikander Ailawadhi, Leyla Bojanini, Aditya Mehta, Suman Biswas, Taimur Sher, Vivek Roy, Prakash Vishnu, Julian Marin-Acevedo, Victoria R. Alegria, Aneel Paulus, Sonikpreet Aulakh, Madiha Iqbal, Rami Manochakian, Winston Tan, Asher Chanan-Khan, Meghna Ailawadhi
Journal: Blood Cancer Journal (2019)

Abstract With improving survivorship in chronic lymphocytic leukemia (CLL), the risk of second primary malignancies (SPMs) has not been systematically addressed. Differences in risk for SPMs among CLL survivors from the Surveillance, Epidemiology, and End Results (SEER) database (1973–2015) were compared to risk of individual malignancies expected in the general population. In ~270,000 person-year follow-up, 6487 new SPMs were diagnosed with a standardized incidence ratio (SIR) of 1.2 (95% CI:1.17–1.23). The higher risk was for both solid (SIR 1.15; 95% CI:1.12–1.18) and hematological malignancies (SIR 1.61; 95% CI:1.5–1.73). The highest risk for SPMs was noted between 2 and 5 months after CLL diagnosis (SIR 1.57; 95% CI:1.41–1.74) and for CLL patients between 50- and 79-years-old. There was a significant increase in SPMs in years 2003–2015 (SIR 1.36; 95% CI:1.3–1.42) as compared to 1973–1982 (SIR 1.19; 95% CI:1.12–1.26). The risk of SPMs was higher in CLL patients who had received prior chemotherapy (SIR 1.38 95% CI:1.31–1.44) as compared to those untreated/treatment status unknown (SIR 1.16, 95% CI:1.13–1.19, p &lt; 0.001). In a multivariate analysis, the hazard of developing SPMs was higher among men, post-chemotherapy, recent years of diagnosis, advanced age, and non-Whites. Active survivorship plans and long-term surveillance for SPMs is crucial for improved outcomes of patients with a history of CLL.
TCT-313 Incidence and Impact of Major Bleeding Events After PCI or CABG for Left Main Coronary Artery Disease: The EXCEL Trial
Authors: Gennaro Giustino, Bjorn Redfors, Roxana Mehran, Shmuel Chen, Patrick Serruys, Joseph Sabik, John Puskas, David Kandzari, Marie-Claude Morice, Nicholas Lembo, William Brown, David Taggart, Zixuan Zhang, Ovidiu Dressler, Stuart Pocock, Ori Ben-Yehuda, Gregg Stone
Journal: Journal of the American College of Cardiology (2019)
Defining ‘T cell exhaustion’
Authors: Christian U. Blank, W. Nicholas Haining, Werner Held, Patrick G. Hogan, Axel Kallies, Enrico Lugli, Rachel C. Lynn, Mary Philip, Anjana Rao, Nicholas P. Restifo, Andrea Schietinger, Ton N. Schumacher, Pamela L. Schwartzberg, Arlene H. Sharpe, Daniel E. Speiser, E. John Wherry, Benjamin A. Youngblood, Dietmar Zehn
Journal: Nature reviews. Immunology (2019)
SAT0187 Use of bone scintigraphy for inflammatory polyarthritis in a teaching hospital rheumatology department
Authors: S Siebert, J Rees, SM Jones
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Bone scintigraphy using <sup>99m</sup>Technetium methylene diphosphonate (<sup>99m</sup>Tc MDP) has been shown to be sensitive in detecting subclinical synovitis<sup>1</sup> but lacks specificity for the aetiology of the articular disease. <sup>99m</sup>Tc MDP scans may therefore have a role to play in identifyinginflammatory polyarthritis (IP) in selected patients, although it isrecognised that they cannot accurately differentiate between differentdegrees of activity in rheumatoid arthritis.<sup>2</sup> <h3>Objectives</h3> To assess the value of <sup>99m</sup>Tc MDP scans in inflammatory polyarthritis. <h3>Methods</h3> All requests for bone scans for IP by the rheumatology department at the University Hospital of Wales over a 2<sup>1</sup>/<sub>2</sub> year period were retrospectively assessed. The indications for the bone scan and the results were recorded. Degenerative changes on bone scan, confirmed on plain xrays, were considered negative for IP. <h3>Results</h3> 94 bone scans were performed in total, of which 68 scans were done looking for possible IP. Of these, 17 (25%) confirmed a pattern of uptake consistent with IP, 6 (9%) were equivocal (possible IP) and 45 (66%) revealed no evidence of IP. 1 patient with a negative <sup>99m</sup>Tc MDP scan subsequently developed psoriatic arthritis with erosions on plain films. In the subgroup of 45 patients with high ESR values, 9 (20%) bone scans suggested an IP, 6 (13%) were equivocal and 30 (67%) were negative. <sup>99m</sup> Tc MDP scans were requested regarding activity of arthritis in 7 patients with known rheumatoid arthritis, of which none were helpful in terms of altering management. 7 patients with seronegative arthritis underwent bone scintigraphy looking for evidence of peripheral joint involvement, which was demonstrated in 3 (43%) patients. <h3>Conclusion</h3> These results suggest that <sup>99m</sup>Tc MDP bone scans may be helpful in patients with normal clinical examination if there is a pattern of uptake suggestive of IP. Negative bone scans can also be helpful in patients with polyarthralgia and elevated inflammatory parameters on blood tests, although it should be stressed that the diagnosis of rheumatoid arthritis remains a clinical one. It is not possible to comment on the degree of activity of arthritis on <sup>99m</sup>Tc MDP scans, and these should therefore not be requested for this. <h3>References</h3> Shearman J, Esdaile J, Hawkins D, Rosenthal L. Arthritis Rheum. 1982;<b>25</b>:83–6 De Bois MHW, Arndt JW, Van der Velde EA, Pauwels EKJ, Breedeveld FC. Br J Rheumatol. 1994;<b>33</b>:67–73
TCT-281 Efficacy and Safety of the Ultrathin-Strut Biodegradable Polymer Sirolimus-Eluting Stents in Routine Clinical Practice: Data From the IRIS-DES Registry
Authors: Junghoon Lee, Ju Hyeon Kim, Yeongjin Jeong, Yujin Yang, KyungJin Choe, Junho Hyun, Sangwoo Park, Sang-Cheol Cho, Hanbit Park, Euihong Ko, Do-Yoon Kang, Pil Hyung Lee, Jung-Min Ahn, Duk-Woo Park, Seung-Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2019)
TCT-638 Diabetes Mellitus Confers Worse Clinical Outcomes at 1 Year Compared to Non–Diabetes Mellitus in an All-Comer Population Implanted With Biodegradable Polymer Everolimus-Eluting Stents
Authors: Hui Wen Sim, Sen He, Mark Chan, Ronald Lee, Huay Cheem Tan, Adrian Low, Edgar Tay, Koo Hui Chan, Poay Huan Loh, Joshua Loh
Journal: Journal of the American College of Cardiology (2019)
A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
Authors: Luis Teixeira, Jacques Medioni, Julie Garibal, Olivier Adotevi, Ludovic Doucet, Marie-Agnès Dragon Durey, Zineb Ghrieb, Jean-Jacques Kiladjian, Mara Brizard, Caroline Laheurte, Maria Wehbe, Elodie Pliquet, Marie Escande, Rémy Defrance, Stephane Culine, Stephane Oudard, Simon Wain-Hobson, Valérie Doppler, Thierry Huet, Pierre Langlade-Demoyen
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Human telomerase reverse transcriptase (hTERT) is highly expressed in &amp;gt;85% of human tumors and is thus considered as a good tumor-associated antigen candidate for vaccine development. We conducted a phase I study to investigate the safety, tolerability, clinical response, and immunogenicity of INVAC-1, a DNA plasmid encoding a modified hTERT protein in patients with relapsed or refractory solid tumors. Patients and Methods: INVAC-1 was either administered by intradermal route followed by electroporation or by Tropis, a needle-free injection system. Safety and tolerability were monitored by clinical and laboratory assessments. Progression-free survival and overall survival were reported using Kaplan–Meier survival analysis. Immunogenicity was studied by ELISpot, Luminex, and Flow Cytometry. Results: Twenty-six patients were treated with INVAC-1 administered at three dose levels (100, 400, and 800 μg). Vaccination was well tolerated and no dose-limiting toxicity was reported. One treatment-related grade 3 SAE was reported. Fifty-eight percent of patients experienced disease stabilization. PFS was 2.7 months, median OS was 15 months, and 1-year survival was reached for 65% of patients. INVAC-1 vaccination stimulated specific anti-hTERT CD4 T-cell response as well as cytotoxic CD8 T-cell response. No evidence of peripheral vaccine-induced immunosuppression was observed. Conclusions: INVAC-1 vaccination was safe, well tolerated, and immunogenic when administered intradermally at the three tested doses in patients with relapsed or refractory cancers. Disease stabilization was observed for the majority of patients (58%) during the treatment period and beyond. See related commentary by Slingluff Jr, p. 529
Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept
Authors: Aurélie Rondon, Sébastien Schmitt, Arnaud Briat, Nancy Ty, Lydia Maigne, Mercedes Quintana, Rosemery Membreno, Brian M. Zeglis, Isabelle Navarro-Teulon, Jean-Pierre Pouget, Jean-Michel Chezal, Elisabeth Miot-Noirault, Emmanuel Moreau, Françoise Degoul
Journal: Theranostics (2019)

et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
TCT-202 Predicting Revascularization Rate of Positive CT-FFR vs. Invasive FFR in Elevated Coronary Calcium Score
Authors: Rajbir Sidhu, Ricardo Kosturakis, Shone Almeida, Eranthi Jayawardena, April Kinninger, Afiachukwu Onuegbu, Emem Udoh, Michael Salerno, Richard Schatz, Paul Teirstein, Curtiss Stinis, Matthew Budoff, Matthew Price, Jeffrey Cavendish, Martin Charlat, George Wesbey
Journal: Journal of the American College of Cardiology (2019)
Outcomes of Older Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis
Authors: Lynn J. Howie, Harpreet Singh, Erik Bloomquist, Suparna Wedam, Laleh Amiri-Kordestani, Shenghui Tang, Rajeshwari Sridhara, Jacqueline Sanchez, Tatiana M. Prowell, Paul G. Kluetz, Belinda L. King-Kallimanis, Jennifer J. Gao, Amna Ibrahim, Kirsten B. Goldberg, Marc Theoret, Richard Pazdur, Julia A. Beaver
Journal: Journal of Clinical Oncology (2019)

Many older women will be treated with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and an aromatase inhibitor (AI), given US Food and Drug Administration approval of three agents in this class. The current pooled analysis examines the efficacy and safety of this combination in older women.We pooled data from three randomized controlled studies (N = 1,827) of different CDK4/6 inhibitors in combination with an AI for initial treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer. The effect of age on progression-free survival was evaluated using Kaplan-Meier estimates and a Cox proportional hazards regression model.For patients age 75 years or older (n = 198) who were treated with a CDK4/6 inhibitor and an AI, hazard ratio was 0.49 (95% CI, 0.31 to 0.76) with an estimated median progression-free survival of 31.1 months (95% CI, 20.2 months to not reached) versus 13.7 months (95% CI, 10.9 months to 24.9 months) for those treated with an AI. Incidence of grade 3 to 4 adverse events was 88.8% in patients age 75 years and older and 73.4% in patients younger than age 75 years. Patients age 75 years or older reported a decline in quality-of-life measures using the EQ-5D regardless of treatment with AI alone or with the addition of a CDK4/6 inhibitor.There was similar efficacy with a CDK4/6 inhibitor in combination with an AI compared with AI alone for first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer in older women compared with younger patients. Patients older than age 75 years experienced higher rates of toxicity, dose modifications, and a decrease from baseline in quality-of-life measures.
Tumor targeted inflammation and coagulation following oncolytic virus therapy compromises blood flow and triggers apoptosis of uninfected tumor cells
Authors: Caroline Breitbach, Harold Atkins, John Bell
Journal: Cancer Research (2008)

456  Oncolytic viruses (OVs) are designed or selected to eliminate malignancies by direct infection and lysis of cancer cells. The purpose of this study was to investigate acute effects of virus replication in vivo. Tumor bearing mice were systemically treated with Vesicular Stomatitis Virus or Vaccinia Virus and tumors were excised at various timepoints post infusion. Immunohistochemical analysis was performed to detect areas of virus infection, apoptosis (active caspase 3), cell proliferation (Ki67), immune cell infiltration and fibrin deposition. Tumor blood flow was visualized by detecting intravenously infused fluorescent microspheres or Hoechst dye on tissue sections. We observed that a significant portion of the in vivo tumor killing activity of OVs is not caused by direct cell lysis but rather by indirect killing of uninfected tumor cells. Early, following only limited virus infection, we observed a loss of blood flow to the interior of the tumor that correlated with massive induction of cellular apoptosis in tumor cells while normal tissue was unaffected. Infection induced neutrophil recruitment to the tumor bed as well as extensive hemorrhagic necrosis and blood clot formation in tumor microvessels. Specifically, fibrin deposition was detected in vessels within the tumor core, while vessels in the tumor rim and normal tissue were not clotted. The viable tumor rim observed at 24 h post infection likely repopulates the tumor as an expanded tumor rim surrounding a necrotic core was observed at 14 and 24 days post treatment. Indeed, quantification of Ki67 staining reveals that malignant cells within the tumor rim continue to replicate after virus treatment. Further studies investigated how manipulation of the host response affects the tumor microenvironment after OV therapy. Depletion of neutrophils in mice prior to VSV administration resulted in decreased fibrin deposition, more extensive growth of the virus and elimination of uninfected tumor apoptosis. Furthermore, blocking blood clot formation with heparin treatment during OV therapy also curtailed vascular shutdown in tumors. Together these results indicate that targeted recruitment of neutrophils and the coagulation cascade to infected tumor beds enhances killing of malignant cells in murine tumors. Importantly, preliminary clinical data suggests onset of avascular necrosis in a liver metastasis of a patient treated with vaccinia virus. Finally, we propose that activation of innate immune cells as well as blood coagulation can be used to enhance the effectiveness of OV therapeutics and will influence strategies for therapeutic dosing. Beyond implications in the field of OV therapeutics, the influence of targeted inflammation in the context of other anticancer therapies warrants further investigation.
TCT-811 Balanced Biventricular Assist Versus Extracorporeal Membrane Oxygenation in Cardiac Arrest
Authors: Erik Packer, Grete Slettom, Atle Solholm, Tom Roar Omdal, Lodve Stangeland, Liqun Zhang, Arve Mongstad, Kjetil Løland, Rune Haaverstad, Ketil Grong, Jan Erik Nordrehaug, Vegard Tuseth
Journal: Journal of the American College of Cardiology (2019)
Strategy of small-caliber endoscopic submucosal dissection for esophageal neoplasia distal to severe stricture
Authors: Noriko Nishiyama, Hideki Kobara, Tatsuo Yachida, Hirohito Mori, Tingting Shi, Keiich Okano, Tsutomu Masaki
Journal: Endoscopy (2019)

When esophageal neoplasia occurs distally to severe stenosis after prior endoscopic submucosal dissection (ESD) [1] [2], a conventional endoscope cannot pass through. Therefore, a small-caliber endoscope (SCE) must be used. Although transnasal ESD of a small esophageal lesion using an SCE without sedation has been reported [3], it is unclear whether an SCE is feasible for standard ESD with compatible devices. Herein, we report the first case of esophageal ESD using an SCE for a circumferential lesion located distally to severe stenosis.
Gastroparesis: a turning point in understanding and treatment
Authors: Madhusudan Grover, Gianrico Farrugia, Vincenzo Stanghellini
Journal: Gut (2019)

Gastroparesis is defined by delayed gastric emptying (GE) and symptoms of nausea, vomiting, bloating, postprandial fullness, early satiety and abdominal pain. Most common aetiologies include diabetes, postsurgical and postinfectious, but in many cases it is idiopathic. Clinical presentation and natural history vary by the aetiology. There is significant morbidity and healthcare utilisation associated with gastroparesis. Mechanistic studies from diabetic animal models of delayed GE as well as human full-thickness biopsies have significantly advanced our understanding of this disorder. An innate immune dysregulation and injury to the interstitial cells of Cajal and other components of the enteric nervous system through paracrine and oxidative stress mediators is likely central to the pathogenesis of gastroparesis. Scintigraphy and
Donor Lymphocyte Cell-Specific Telomere Length and Causes of Death after Unrelated Hematopoietic Cell Transplant in Patients with Marrow Failure
Authors: Shahinaz M Gadalla, Geraldine Aubert, Tao Wang, Michael Haagenson, Stephen R. Spellman, Lingxiao Wang, Hormuzd Katki, Stephanie J Lee, Sharon A Savage
Journal: Blood (2017)
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer
Authors: H. Yoshioka, M. Shimokawa, T. Seto, S. Morita, Y. Yatabe, I. Okamoto, J. Tsurutani, M. Satouchi, T. Hirashima, S. Atagi, K. Shibata, H. Saito, S. Toyooka, N. Yamamoto, K. Nakagawa, T. Mitsudomi
Journal: Annals of Oncology (2019)

Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) gefitinib compared with cisplatin plus docetaxel (CD) as the first-line treatment of stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. This report presents final overall survival (OS) data.
Quality Indicators for Bladder Cancer Services: A Collaborative Review
Authors: Jeffrey J. Leow, James W.F. Catto, Jason A. Efstathiou, John L. Gore, Ahmed A. Hussein, Shahrokh F. Shariat, Angela B. Smith, Alon Z. Weizer, Manfred Wirth, J. Alfred Witjes, Quoc-Dien Trinh
Journal: European Urology (2019)